SPOTLIGHT: FDA delays anemia approval

Roche says that the FDA has delayed final approval of Mircera, a new anemia drug. Roche is staying mum about exactly what questions the FDA wants answered before approval, but a company spokesman says that the agency won't approve any new anemia drugs until it has a chance to review the class of drugs aimed at treating anemia in kidney patients. Mircera is intended to compete with Aranesp and Epogen, which have come under intense scrutiny recently. Report

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.